Zacks Company Profile for Sorrento Therapeutics, Inc. (SRNE : NSDQ) |
|
|
|
Company Description |
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California.
Number of Employees: 799 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.58 |
Daily Weekly Monthly
 |
20 Day Moving Average: 10,216,579 shares |
Shares Outstanding: 388.95 (millions) |
Market Capitalization: $614.53 (millions) |
Beta: 2.43 |
52 Week High: $11.07 |
52 Week Low: $1.15 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-7.06% |
4.68% |
12 Week |
-39.46% |
-33.44% |
Year To Date |
-66.02% |
-58.48% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Henry Ji - Chairman; Chief Executive Officer and President
Dorman Followwill - Director
Yue Alexander Wu - Director
Kim D. Janda - Director
Jaisim Shah - Director
|
|
Peer Information
Sorrento Therapeutics, Inc. (CORR.)
Sorrento Therapeutics, Inc. (RSPI)
Sorrento Therapeutics, Inc. (CGXP)
Sorrento Therapeutics, Inc. (BGEN)
Sorrento Therapeutics, Inc. (GTBP)
Sorrento Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 83587F202
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 05/25/22
|
|
Share - Related Items
Shares Outstanding: 388.95
Most Recent Split Date: (:1)
Beta: 2.43
Market Capitalization: $614.53 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.22 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.81 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 05/25/22 |
|
|
|
|